CClinicalTrials.gg
CompletedNCT03705026Updated Sep 16, 2020

Relationship Between Genetic Polymorphism and Postoperative Nausea and Vomiting in Chinese Han Population

An observational study in Breast Neoplasms and Anesthesia, General, sponsored by Fujian Medical University Union Hospital. Completed. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Fujian Medical University Union Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
568
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

Postoperative nausea and vomiting ( PONV ) is one of the common complications after general anesthesia while genetic factors may play an important role in Postoperative nausea and vomiting. In this study, the investigators investigated the relationship between gene polymorphism ( such as single nucleotide polymorphism ) of the gene HTR3A ( 5-hydroxytryptamine receptor 3A ), HTR3B ( 5-hydroxytryptamine receptor 3B ), HTR3C ( 5-hydroxytryptamine receptor 3C ) and TACR1 ( tachykinin receptor 1 ) etc. with nausea and vomiting after general anesthesia. Simultaneously, the investigators explored the influencing factors of nausea and vomiting.

Read the detailed description

Materials and methods:

Demographic data and risk factors responsible for PONV, including the history of PONV and motion sickness, were collected preoperatively by interviewing participants the day before anesthesia.

All study subjects received a standardized anesthesia regimen. General anesthesia was induced by midazolam 0.04 mg/kg, propofol 1.5 mg/kg, sufentanil 0.4 μg/kg, and cisatracurium 0.2 mg/kg (to facilitate tracheal intubation) given intravenously.Participants' lungs were ventilated with 50% oxygen in air.

During general anesthesia, concentration of sevoflurane maintained 1.0% to 3.0% at the discretion of anesthetist who was not involved in the study. General anesthesia also uses propofol 1 mg kg-1 h-1 and sufentanil 0.1 μg kg-1 h-1 by continuous intravenous infusion. An Entropy index monitor was used to maintain the appropriate anesthesia depth by 40-60. Participants received a repeated bolus of sufentanil 0.1 μg/kg or cisatracurium intravenously on demand.

After surgery the investigators recorded the data such as Anesthesia duration, doses of sufentanil and propofol and so on.

At the end of surgery and after returning to the ward, flurbiprofen axetil 50 mg injection i.v. was administered as an analgesic therapy, respectively. Cholinesterase inhibitor-based neuromuscular reversal drugs and vitamine B6 were not administered after surgery. Bucinnazine hydrochloride 100 mg intramuscular injection (i.m.) as a rescue medication was administered to any participant whose visual analogue scale/score (VAS) was > 3.

Ondansetron was given intravenously to the participants if necessary or requested . Unaware of the genotypes of the subjects, the investigators collected the participants' data including nausea, vomiting and pain.

02

Conditions studied

  • Breast Neoplasms
  • Anesthesia, General

Keywords

  • postoperative nausea and vomiting
  • general anesthesia
  • breast surgery
  • single nucleotide polymorphism
03

In context

Breast Neoplasms

12,543 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 568 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Fujian Medical University Union Hospital is the lead sponsor of 100 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Han population who were admitted to department of breast surgery, Fujian Medical University Union Hospital.

Inclusion criteria

  • Undergoing breast surgery with general anesthesia
  • American Society of Anesthesiologists Physical Status Classifications 1-2
  • No history of smoking
  • body mass index (BMI) \<35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Declined to participate
  • Had used antiemetics, steroids, H2 antagonists, anticholinergics, antihistamines, butyrophenones, phenothiazines, metoclopramide or opioids within 24 hours
  • Gastroesophageal reflux, gastrointestinal obstruction or ulcer, vestibular or hearing dysfunction
  • Liver impairment, renal impairment, psychiatric disorder, chronic pain
  • Pregnant and lactating patients
  • Requiring postoperative patient-controlled analgesia
  • Requiring prophylactic use of antiemetics
  • Allergic to drugs related in the study
  • Receiving chemotherapy within one week before surgery
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
568 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Whether the participants occur nausea or not

    Nausea was defined as a feeling of wanting to throw up or about to throw up.

    Time frame: Period of 0 to 6 hours after surgery

  2. Whether the participants occur vomiting or not

    Vomiting was defined as the discharge of the stomach contents, while retching as an involuntary attempt to vomit that did not produce stomach contents. Retching was considered as vomiting.

    Time frame: Period of 0 to 6 hours after surgery

  3. Whether the participants occur nausea or not

    Nausea was defined as a feeling of wanting to throw up or about to throw up.

    Time frame: Period of 6 to 24 hours after surgery

  4. Whether the participants occur vomiting or not

    Vomiting was defined as the discharge of the stomach contents, while retching as an involuntary attempt to vomit that did not produce stomach contents. Retching was considered as vomiting.

    Time frame: Period of 6 to 24 hours after surgery

Secondary outcomes

  1. Level of nausea

    The level of participants' nausea was rated on four-point scales: 0=no nausea; 1=mild nausea with activities; 2=mild nausea at rest; and 3=se-vere nausea at rest.

    Time frame: Within 24 hours after surgery

  2. Number of vomiting

    The investigators defined an emetic episode as a single occurrence of vomiting/retching or as a series of immediately successive vomiting/retching. However, vomiting/retching had to be separated by at least 1 minute to be classified as a single emetic episode.

    Time frame: Within 24 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Yan T, Su J, Zhou L, Zhang L. Polymorphisms of 5-hydroxytryptamine receptor type 3B gene and clinical characteristics for vomiting after breast surgery in chinese han female population. J Clin Pharm Ther. 2021 Aug;46(4):936-941. doi: 10.1111/jcpt.13386. Epub 2021 Feb 19. PubMed 33605481 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03705026
Lead sponsor
Fujian Medical University Union Hospital
Responsible party
Sponsor
First posted
Oct 15, 2018
Start date
Sep 1, 2013
Primary completion
Jan 31, 2020
Completion
Jan 31, 2020
Last update
Sep 16, 2020

Study contacts

Liangcheng Zhang, Ph.D
principal investigator · Fujian Medical University Union Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion